Blog
RSS FeedPosted by Michael Wonder on 02 Apr 2024
Mirum Pharmaceuticals’ Livmarli (maralixibat oral solution) receives positive reimbursement recommendation by Canada’s CADTH for patients with cholestatic pruritus in Alagille syndrome
2 April 2024 - Positive HTA recommendation for reimbursement signifies an important milestone towards public funding to treat eligible patients with ...
Posted by Michael Wonder on 05 Mar 2024
Nine drug formularies in Canada list Evenity for reimbursement for the treatment of osteoporosis in post-menopausal women as high risk of fracture
5 March 2024 - Multiple formulary listings are a step forward to ensuring that post-menopausal women have access to medicines ...
Posted by Michael Wonder on 04 Mar 2024
Findings from the Lean review of our drug reimbursement review program
29 February 2024 - Last year, CADTH communicated several improvements to our drug reimbursement review program, including a Lean review ...
Posted by Michael Wonder on 29 Feb 2024
Collaborating to help improve access to drugs for rare diseases
29 February 2024 - On Rare Disease Day — a day when the international community raises awareness about rare conditions ...
Posted by Michael Wonder on 24 Feb 2024
Drug insurance: a single payer pharmacare program would jeopardise coverage quality for 21 million Canadians
22 February 2024 - Imposing a single payer universal drug insurance plan on all Canadians would jeopardise coverage quality for ...
Posted by Michael Wonder on 08 Feb 2024
Knight Therapeutics announces launch of Bijuva in Canada
6 February 2024 - Knight Therapeutics announced today the launch of Bijuva (oestradiol and progesterone) capsules in Canada. ...
Posted by Michael Wonder on 08 Feb 2024
HLS announces that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan
6 February 2024 - Public reimbursement for Vascepa is now available in Ontario, Quebec, British Columbia, Saskatchewan, New Brunswick, Northwest Territories, ...
Posted by Michael Wonder on 05 Feb 2024
Sumitomo Pharma and Pfizer Canada announce availability of Myfembree in Canada
31 January 2024 - In partnership with Sumitomo, Pfizer is proud to announce that supply of Myfembree (relugolix 40 mg, estradiol ...
Posted by Michael Wonder on 18 Jan 2024
Sudbury, Ontario family finally gets coverage for drug to treat daughter's rare epilepsy
16 January 2024 - Fenfluramine costs more than $3,000 a month and is not approved by Health Canada. ...
Posted by Michael Wonder on 19 Dec 2023
The Government of Canada announces the creation of the Canadian Drug Agency
18 December 2023 - Helping make Canada's drug system more sustainable and better prepared for the future. ...
Posted by Michael Wonder on 30 Nov 2023
Prevalence and nature of manufacturer-sponsored patient support programs for prescription drugs in Canada: a cross-sectional study
27 November 2023 - Of the 2556 prescription drugs marketed by 89 companies in the study period, 256 (10.0%) had a ...
Posted by Michael Wonder on 13 Nov 2023
Informing real-time decisions with post-market drug evidence
10 November 2023 - It’s been one year since CADTH launched the Post-Market Drug Evaluation (PMDE) Program to provide decision-makers with ...
Posted by Michael Wonder on 08 Nov 2023
Mitsubishi Tanabe Pharma Canada announces that Company's oral treatment formulation for amyotrophic lateral sclerosis has been added to the provincial drug plans in Prince Edward Island, Newfoundland and Labrador
7 November 2023 - Mitsubishi Tanabe Pharma Canada today announced that Radicava oral suspension (edaravone) is now covered under the Prince ...
Posted by Michael Wonder on 02 Nov 2023
Rhythm Pharmaceuticals receives positive CADTH reimbursement recommendation for Imcivree (setmelanotide)
2 November 2023 - Recommendation based on demonstrated clinical benefit in Phase 3 trial. ...
Posted by Michael Wonder on 27 Oct 2023
Drugs are outrageously expensive—Canada found a way to fight back
27 October 2023 - Latuda is a drug to treat schizophrenia. It costs about $4,000 per month in the US. ...